You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

Contact a GSK Sales Representative

Chat with Medical Information


Epidemiology of invasive meningococcal disease (IMD) caused by serogroup B strains (MenB)

Go to Close Top

From 2007 to 2011, infants under 1 year of age had the highest risk of MenB.

  • From 2007 to 2011, the incidence of MenB was the highest among infants younger than 1 year of age, followed by children 1 to 4 years of age, and adolescents 15 to 19 years of age. 1*

MenB average annual incidence rates in Canada,* 2007-2011 1

The graph shows the Incidence of MenB by age in Canada (2007-2011). The incidence rate per 100,000 of population was 5.78 for infants less than 1 year of age, 1.40 for children 1 to 4 years of age, 0.23 for 5- to 9-year olds, 0.23 for 10- to 14-year olds, 0.73 for adolescents 15 to 19 years of age, and 0.43 for adults 20 to 24 years of age.

Adapted from the 2014 PHAC NACI statement 1

*BEXSERO is indicated for active immunization of individuals from 2 months through 25 years old against invasive disease caused by Neisseria meningitidis serogroup B strains. BEXSERO is not indicated for use in individuals >25 years of age.

BEXSERO is not expected to provide protection against all circulating meningococcal serogroup B strains. Protection against IMD caused by other serogroups has not been studied. Therefore, protection against other serogroups should not be assumed with BEXSERO. As with any vaccine, BEXSERO may not protect all vaccine recipients. 

Meningococcal disease caused by serogroup B strains (MenB) caused the majority of IMD cases in Canada since the early 2000s (0.33 cases per 100,000; an average of 196 cases of IMD reported annually 2006-2011) 2

Percentage of reported IMD cases by serogroup (2013-2017; N=548) 3†

The graph shows the Percentage of average reported IMD cases (2011 to 2015).

* Meningococcal disease caused by Neisseria meningitidis group B strains.
† Based on most recent data available

* BEXSERO is indicated for active immunization of individuals from 2 months through 25 years old against invasive disease caused by Neisseria meningitidis serogroup B strains. BEXSERO is not indicated for use in individuals >25 years of age.

BEXSERO is not expected to provide protection against all circulating meningococcal serogroup B strains. Protection against IMD caused by other serogroups has not been studied. Therefore, protection against other serogroups should not be assumed with BEXSERO. As with any vaccine, BEXSERO may not protect all vaccine recipients. 

References:

  1. An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI). Advice for the use of the Multicomponent Meningococcal Serogroup B (4CMenB) Vaccine. April 2014. Available at: http://publications.gc.ca/collections/collection_2014/aspc-phac/HP40-104-2014-eng.pdf.
  2. Government of Canada. Invasive meningococcal disease. Accessed February 14, 2018. Available at https://www.canada.ca/en/public-health/services/immunization/vaccine-preventable-diseases/invasive-meningococcal-disease/health-professionals.html.
  3. An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI). The Use of Bivalent Factor H Binding Protein Meningococcal Serogroup B (MenB-fHBP) Vaccine for the Prevention of Meningococcal B Disease. December 2019. Available at: https://www.canada.ca/content/dam/phac-aspc/documents/services/publications/vaccines-immunization/naci-imd-b-statement-eng.pdf.

This page is for Healthcare Professionals only. If you are not a Healthcare Professional, please visit Bexsero.ca.

Français